You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Myeloablative Autologous Gene Editing

Showing 1 - 25 of 9,686
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

SCD Curative Therapies

Not yet recruiting
  • Sickle Cell Disease
  • +3 more
    • Washington, District of Columbia
    • +4 more
    Jun 28, 2022

    Alpha Thalassemia Hemoglobin H Constant Spring, Hemoglobinopathies, Hereditary Diseases Trial in Nanning (RM-004)

    Recruiting
    • Alpha Thalassemia Hemoglobin H Constant Spring
    • +2 more
    • RM-004
    • Nanning, Guangxi, China
      The 923rd Hospital of Joint Logistics Support Force of People's
    Oct 25, 2023

    Sickle Cell Disease Trial in Boston (BEAM-101)

    Not yet recruiting
    • Sickle Cell Disease
    • BEAM-101
    • Boston, Massachusetts
      Boston Children's Hospital
    Jul 11, 2022

    Gastrointestinal Epithelial Cancer, Gastrointestinal Tumors, Cancer of Gastrointestinal Tract Trial in Minneapolis

    Recruiting
    • Gastrointestinal Epithelial Cancer
    • +10 more
    • Minneapolis, Minnesota
      Masonic Cancer Center, University of Minnesota
    Aug 20, 2021

    NSCLC, Metastatic Non Small Cell Lung Cancer, Stage IV NSCLC Trial in Duarte, Minneapolis (Fludarabine, Cyclophosphamide, CISH

    Not yet recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +5 more
    • Duarte, California
    • +1 more
    Dec 7, 2022

    Sickle Cell Disease Trial in Los Angeles, Oakland (CRISPR_SCD001)

    Not yet recruiting
    • Sickle Cell Disease
    • Los Angeles, California
    • +1 more
    Apr 25, 2022

    l Gene Editing Therapy for Cardiovascular Disease

    Not yet recruiting
    • Atherosclerotic Cardiovascular Disease
    • +2 more
      • Auckland, New Zealand
      • +2 more
      Oct 31, 2023

      Cerebral Adrenoleukodystrophy (CALD) Trial in Worldwide (Lenti-D)

      Active, not recruiting
      • Cerebral Adrenoleukodystrophy (CALD)
      • Lenti-D
      • Palo Alto, California
      • +7 more
      Mar 22, 2022

      Beta-Thalassemia Trial (CS-101 injection)

      Not yet recruiting
      • Beta-Thalassemia
      • CS-101 injection
      • (no location specified)
      Sep 27, 2023

      Congenital Hearing Loss Trial in Shanghai (HG205)

      Not yet recruiting
      • Congenital Hearing Loss
      • HG205
      • Shanghai, China
        Eye & ENT Hospital of Fudan University
      Aug 29, 2023

      Sickle Cell Disease Trial in Birmingham, Palo Alto, Saint Louis (GPH101 Drug Product)

      Active, not recruiting
      • Sickle Cell Disease
      • GPH101 Drug Product
      • Birmingham, Alabama
      • +2 more
      Jan 5, 2023

      Sickle Cell Disease Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Non-myeloablative haploidentical

      Not yet recruiting
      • Sickle Cell Disease
      • Non-myeloablative haploidentical peripheral blood stem celltransplantation with briquilimab and abatacept
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Dec 4, 2023

      Gene Editing as a Therapeutic Approach for Rett Syndrome

      Recruiting
      • Rett Syndrome
      • Gene editing in vitro
      • Siena, Italy
        University of Siena
      Feb 13, 2023

      Duchenne Muscular Dystrophy Trial in Worcester (CRD-TMH-001)

      Enrolling by invitation
      • Duchenne Muscular Dystrophy
      • Worcester, Massachusetts
        UMass Chan Medical School
      Aug 22, 2022

      Liver Cancer Trial in Wuhan (Autologous Tumor Infiltrating Lymphocytes)

      Recruiting
      • Liver Cancer
      • Autologous Tumor Infiltrating Lymphocytes
      • Wuhan, China
        Tongji Hospital
      Oct 9, 2023

      Advanced Breast Cancer, Advanced Lung Cancer Trial (Tumor-infiltrating lymphocytes, IL-2)

      Not yet recruiting
      • Advanced Breast Cancer
      • Advanced Lung Cancer
      • Tumor-infiltrating lymphocytes
      • IL-2
      • (no location specified)
      Oct 26, 2023

      ß Thalassemia Major Trial in Shanghai (?-globin reactivated autologous hematopoietic stem cells)

      Active, not recruiting
      • β Thalassemia Major
      • γ-globin reactivated autologous hematopoietic stem cells
      • Shanghai, Shanghai, China
        Shanghai Bioray Laboratories Inc.
      Oct 9, 2022

      Lymphoma, Non-Hodgkin Trial in Saint Louis (Stem cell infusion, TLI, Anti-thymocyte globulin)

      Active, not recruiting
      • Lymphoma, Non-Hodgkin
      • Stem cell infusion
      • +5 more
      • Saint Louis, Missouri
        Washington University
      Jan 17, 2023

      Leukocyte Adhesion Defect - Type I Trial in Madrid (RP-L201)

      Withdrawn
      • Leukocyte Adhesion Defect - Type I
      • RP-L201
      • Madrid, Spain
        Hospital Infantil Universitario Niño Jesús (HIUNJ)
      Nov 23, 2021

      Viral Keratitis, Blindness Eye, Herpes Simplex Virus Infection Trial in Shanghai (BD111 Adult single group Dose)

      Completed
      • Viral Keratitis
      • +3 more
      • BD111 Adult single group Dose
      • Shanghai, Shanghai, China
        Eye & Ent Hospital of Fudan University
      Aug 20, 2022

      Solid Tumor Trial in Shanghai (BEN101)

      Not yet recruiting
      • Solid Tumor
      • BEN101
      • Shanghai, Shanghai, China
      • +1 more
      Apr 14, 2023

      MPS I Trial in Oakland (SB-318)

      Terminated
      Has Results
      • MPS I
      • SB-318
      • Oakland, California
        UCSF Benioff Children's Hospital Oakland
      Jan 6, 2023

      Sickle Cell Disease Trial in Boston (Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA

      Recruiting
      • Sickle Cell Disease
      • Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
      • Los Angeles, California
      • +8 more
      Jan 10, 2023

      Phenylketonurias, PAH Deficiency, Phenylketonuria Trial in United States (HMI-103)

      Recruiting
      • Phenylketonurias
      • +2 more
      • Orange, California
      • +5 more
      Oct 26, 2022

      Endocrine/Neuroendocrine, NSCLC, Breast Cancer Trial run by the National Cancer Institute (NCI) (Fludarabine, Cyclophosphamide,

      Recruiting
      • Endocrine/Neuroendocrine
      • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Aug 24, 2022